好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

EDSS and Timed 25 Foot Walk Correlate with Spinal Cord Areas: Baseline Results from the SPI2 Clinical Trial of MD-1003 (high-dose biotin) in Progressive Multiple Sclerosis
Multiple Sclerosis
P3 - Poster Session 3 (5:30 PM-6:30 PM)
15-023

To determine whether clinical measures of disability (timed 25-foot walk [T25FW] and Expanded Disability Status Scale [EDSS]) correlate with total cervical spinal cord area as measured by MRI by phase-sensitive inversion recovery (PSIR) imaging in a phase 3 randomized clinical trial for progressive multiple sclerosis (MS).

Cross-sectional studies indicated a strong relationship between MS disability and spinal cord areas but these metrics have not been investigated in a multi-center dataset or within the context of a randomized controlled trial. The SPI2 study is a phase 3, placebo-controlled, randomized trial investigating the efficacy and safety of MD1003 (high-dose biotin) in 642 participants with progressive forms of MS.

Spinal cord MRI was acquired at 60 of 92 study centers that had Phillips or Siemens 1.5 or 3.0 Tesla MRI scanners. Sites with General Electric scanners did not participate. PSIR sequences at vertebral disc levels C2-C3 and C3-C4 were acquired at baseline (prior to randomization). Total cord areas were measured using a semi-automatic method. LASSO subset selection regression models were used to correlate the average total cord areas with sex, disease duration, onset age, disease course, and combinations of T25FW and EDSS.

Baseline cervical spinal cord MRI scans were available for 120 primary progressive MS (PPMS) and 204 secondary progressive MS (SPMS) participants. A model including both walk time and EDSS had: R2=0.15 with onset age (p<.0001) and (T25FW p<.0001) significantly contributing. A model without T25FW had R2=0.14 with onset age (p<.0001) and EDSS (p=.0002) significantly contributing. Disease course (secondary progressive MS vs primary progressive MS) was not significant in these relationships.

These results demonstrate the feasibility of implementing cross-platform, PSIR cervical cord MRI in a global, multi-center, multi-platform, phase 3 clinical trial. These results validate proposed correlations between total cervical cord areas using PSIR MRI and clinical disability outcomes. 

Authors/Disclosures
Valerie A. Block, DPTSc (University of California, San Francisco)
PRESENTER
Dr. Block has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. The institution of Dr. Block has received research support from National MS Society.
Amber M. Alexander Amber M. Alexander has nothing to disclose.
Nico Papinutto No disclosure on file
No disclosure on file
No disclosure on file
Douglas L. Arnold, MD, FAAN (Montreal Neurological Institute, McGill Univ) Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for BMS. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Frequency Therapeutics. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Merck. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Arnold has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Roche. Dr. Arnold has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sanofi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Shionogi. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Xfacto communications. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for EMD Serono. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biohaven. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Find therapeutics. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GSK. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Idorsia. Dr. Arnold has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Kiniksa. Dr. Arnold has received personal compensation in the range of $100,000-$499,999 for serving as a Consultant for Clario.
Frederic Sedel No disclosure on file
Bruce A. Cree, MD, PhD, MAS, FAAN (UCSF, Multiple Sclerosis Center) The institution of Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi. The institution of Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. The institution of Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Cree has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Neuron23. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boston Pharma. Dr. Cree has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Hexal/Sandoz. Dr. Cree has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Immunic AG. The institution of Dr. Cree has received research support from Genentech. The institution of Dr. Cree has received research support from Kyverna. Dr. Cree has received publishing royalties from a publication relating to health care.
Roland G. Henry, PhD (University of California, San Francisco) Dr. Henry has received personal compensation in the range of $500-$4,999 for serving as a Consultant for MEDDAY. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Henry has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Henry has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Sanofi/Genzyme.